{
    "root": "04d373d5-4825-49dc-89a4-65dc2dd6e498",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "Diclofenac Sodium/Misoprostol",
        "suffix": {
            "text": "diclofenac-sodium-misoprostol"
        }
    },
    "value": "20250314",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "HYDROGENATED CASTOR OIL",
            "code": "ZF94AP8MEY"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        },
        {
            "name": "METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER",
            "code": "NX76LV5T8J"
        },
        {
            "name": "DICLOFENAC SODIUM",
            "code": "QTG126297Q"
        },
        {
            "name": "MISOPROSTOL",
            "code": "0E43V0BB57"
        }
    ],
    "indications": "diclofenac sodium misoprostol delayed-release tablets indicated treatment signs symptoms osteoarthritis rheumatoid arthritis adult patients high risk developing nsaid-induced gastric duodenal ulcers complications . list factors may increase risk nsaid-induced gastric duodenal ulcers complications [ ( 5.3 ) ] .",
    "contraindications": "• lowest effective shortest duration consistent individual patient treatment goals . ( 2.1 ) • osteoarthritis : recommended maximal gi protection one tablet ( containing 50 mg diclofenac 200 mcg misoprostol ) three times daily . diclofenac higher 150 mg/day recommended . ( 2.2 ) • rheumatoid arthritis : recommended maximal gi protection one tablet ( containing 50 mg diclofenac 200 mcg misoprostol ) three four times daily . diclofenac higher 200 mg/day recommended . ( 2.3 ) • modifications due intolerance , full prescribing information . ( 2.2 , 2.3 )",
    "warningsAndPrecautions": "diclofenac sodium misoprostol delayed-release tablets , usp supplied uncoated tablets strengths either 50 mg diclofenac sodium/200 mcg misoprostol 75 mg diclofenac sodium/200 mcg misoprostol . 75 mg/200 mcg strength white off-white , round , biconvex uncoated tablet , debossed “ 75 ” one side plain side . strengths supplied : bottles 30 tablets ndc 68788-8214-3 bottles 60 tablets ndc 68788-8214-6 store 20° 25°c ( 68° 77°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "diclofenac sodium misoprostol delayed-release tablets contraindicated following patients : •pregnancy . misoprostol , component diclofenac sodium misoprostol delayed-release tablets , pregnancy result maternal fetal harm , including uterine rupture , abortion , premature birth , birth defects [ ( 5.1 ) ( 8.1 ) ] •in setting coronary artery bypass graft ( cabg ) surgery [ ( 5.2 ) ] •active gastrointestinal bleeding [ ( 5.3 ) ] •history asthma , urticaria , allergic-type taking aspirin nsaids . severe , sometimes fatal , anaphylactic nsaids reported patients [ ( 5.8 , 5.9 ) ] •known hypersensitivity ( e.g . , anaphylactic serious skin ) diclofenac sodium misoprostol , prostaglandins , components product [ ( 5.8 , 5.10 ) ]",
    "indications_original": "Diclofenac sodium and misoprostol delayed-release tablets are indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in adult patients at high risk of developing NSAID-induced gastric and duodenal ulcers and their complications. For a list of factors that may increase the risk of NSAID-induced gastric and duodenal ulcers and their complications     [see Warnings and Precautions (       5.3)]     .",
    "contraindications_original": "• Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals. ( 2.1 ) • Osteoarthritis: The recommended dosage for maximal GI protection is one tablet (containing 50 mg of diclofenac and 200 mcg of misoprostol) three times daily. A dosage of diclofenac higher than 150 mg/day is not recommended. ( 2.2 ) • Rheumatoid Arthritis: The recommended dosage for maximal GI protection is one tablet (containing 50 mg of diclofenac and 200 mcg of misoprostol) three or four times daily. A dosage of diclofenac higher than 200 mg/day is not recommended. ( 2.3 ) • For dosage modifications due to intolerance, see the full Prescribing Information. ( 2.2 , 2.3 )",
    "warningsAndPrecautions_original": "Diclofenac sodium and misoprostol delayed-release tablets, USP are supplied as a uncoated tablets in dosage strengths of either 50 mg diclofenac sodium/200 mcg misoprostol or 75 mg diclofenac sodium/200 mcg misoprostol.\n                  75 mg/200 mcg dosage strength is a white to off-white, round, biconvex uncoated tablet, debossed  with “D 75 M” on one side and plain on other side. \n                  \n                  The dosage strengths are supplied in:\n                  \n                     \n                         Bottles of 30 Tablets\tNDC 68788-8214-3\n                     \n                         Bottles of 60 Tablets\tNDC 68788-8214-6\n                  \n                  \n                     Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Diclofenac sodium and misoprostol delayed-release tablets are contraindicated in the following patients:\n                  \n                     \n                        •Pregnancy. Use of misoprostol, a component of diclofenac sodium and misoprostol delayed-release tablets, during pregnancy can result in maternal and fetal harm, including uterine rupture, abortion, premature birth, or birth defects       [see Warnings and Precautions (         5.1) and Use in Specific Populations (         8.1)]       \n                     \n                     \n                        •In the setting of coronary artery bypass graft (CABG) surgery       [see Warnings and Precautions (         5.2)]       \n                     \n                     \n                        •Active gastrointestinal bleeding       [see Warnings and Precautions (         5.3)]       \n                     \n                     \n                        •History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients       [see Warnings and Precautions (         5.8,         5.9)]       \n                     \n                     \n                        •Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac sodium and misoprostol, other prostaglandins, or any components of the drug product       [see Warnings and Precautions (         5.8,         5.10)]"
}